131 related articles for article (PubMed ID: 8089554)
1. Tosulfloxacin versus norfloxacin for prevention of infections in chemotherapy-induced neutropenic patients.
Mori S; Ohashi K; Akiyama H; Shoji H; Sato H; Tanikawa S; Sakamaki H; Onozawa Y
Kansenshogaku Zasshi; 1994 Jul; 68(7):872-8. PubMed ID: 8089554
[TBL] [Abstract][Full Text] [Related]
2. Effect of discontinuing prophylaxis with norfloxacin in patients with hematologic malignancies and severe neutropenia. A matched case-control study of the effect on infectious morbidity.
Martino R; Subira M; Altés A; López R; Sureda A; Domingo-Albós A; Pericas R; Brunet S
Acta Haematol; 1998; 99(4):206-11. PubMed ID: 9644298
[TBL] [Abstract][Full Text] [Related]
3. Prophylactic co-trimoxazole versus norfloxacin in neutropenic children--perspective randomized study.
Cruciani M; Concia E; Navarra A; Perversi L; Bonetti F; Aricò M; Nespoli L
Infection; 1989; 17(2):65-9. PubMed ID: 2654019
[TBL] [Abstract][Full Text] [Related]
4. [Prophylaxis with fluoroquinolones in patients with neutropenia].
Brodsky AL; Minissale CJ; Melero MJ; Sánchez Avalos JC
Medicina (B Aires); 1993; 53(5):401-7. PubMed ID: 8201928
[TBL] [Abstract][Full Text] [Related]
5. Quinolone-based antibacterial chemoprophylaxis in neutropenic patients: effect of augmented gram-positive activity on infectious morbidity. National Cancer Institute of Canada Clinical Trials Group.
Bow EJ; Mandell LA; Louie TJ; Feld R; Palmer M; Zee B; Pater J
Ann Intern Med; 1996 Aug; 125(3):183-90. PubMed ID: 8686975
[TBL] [Abstract][Full Text] [Related]
6. Prevention of bacterial infection in neutropenic patients with hematologic malignancies. A randomized, multicenter trial comparing norfloxacin with ciprofloxacin. The GIMEMA Infection Program. Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto.
Ann Intern Med; 1991 Jul; 115(1):7-12. PubMed ID: 2048868
[TBL] [Abstract][Full Text] [Related]
7. Comparison of norfloxacin and pefloxacin in the prophylaxis of bacterial infection in neutropenic cancer patients.
D'Antonio D; Iacone A; Fioritoni G; Betti S; Dell'Isola M; Quaglietta AM; Accorsi P; Pantalone V; Recchia A; Piergallini A
Drugs Exp Clin Res; 1992; 18(4):141-6. PubMed ID: 1451644
[TBL] [Abstract][Full Text] [Related]
8. The new fluorinated quinolones for antimicrobial prophylaxis in neutropenic cancer patients.
Del Favero A; Menichetti F
Eur J Cancer; 1993; 29A Suppl 1():S2-6. PubMed ID: 8427721
[TBL] [Abstract][Full Text] [Related]
9. Comparison of norfloxacin with cotrimoxazole for infection prophylaxis in acute leukemia. The trade-off for reduced gram-negative sepsis.
Bow EJ; Rayner E; Louie TJ
Am J Med; 1988 May; 84(5):847-54. PubMed ID: 3284340
[TBL] [Abstract][Full Text] [Related]
10. Comparison of ciprofloxacin, ofloxacin and pefloxacin for the prevention of the bacterial infection in neutropenic patients with haematological malignancies.
D'Antonio D; Piccolomini R; Iacone A; Fioritoni G; Parruti G; Betti S; Quaglietta AM; Accorsi P; Dell'Isola M; Favalli C
J Antimicrob Chemother; 1994 Apr; 33(4):837-44. PubMed ID: 8056702
[TBL] [Abstract][Full Text] [Related]
11. [Prevention and treatment of febrile neutropenia].
Montemurro F; Gallicchio M; Aglietta M
Tumori; 1997; 83(2 Suppl):S15-9. PubMed ID: 9235724
[TBL] [Abstract][Full Text] [Related]
12. Bacterial infections in cirrhosis: epidemiological changes with invasive procedures and norfloxacin prophylaxis.
Fernández J; Navasa M; Gómez J; Colmenero J; Vila J; Arroyo V; Rodés J
Hepatology; 2002 Jan; 35(1):140-8. PubMed ID: 11786970
[TBL] [Abstract][Full Text] [Related]
13. Norfloxacin for prevention of bacterial infections in granulocytopenic patients.
Winston DJ; Ho WG; Champlin RE; Karp J; Bartlett J; Finley RS; Joshi JH; Talbot G; Levitt L; Deresinski S
Am J Med; 1987 Jun; 82(6B):40-6. PubMed ID: 3037899
[TBL] [Abstract][Full Text] [Related]
14. Emerging role of quinolones in the prevention of gram-negative bacteremia in neutropenic cancer patients and in the treatment of enteric infections.
Bow EJ; Louie TJ
Clin Invest Med; 1989 Feb; 12(1):61-8. PubMed ID: 2646056
[TBL] [Abstract][Full Text] [Related]
15. Moxifloxacin is more effective than tosufloxacin in reducing chemotherapy-induced febrile neutropenia in patients with hematological malignancies.
Shinohara A; Yoshiki Y; Masamoto Y; Hangaishi A; Nannya Y; Kurokawa M
Leuk Lymphoma; 2013 Apr; 54(4):794-8. PubMed ID: 22978686
[TBL] [Abstract][Full Text] [Related]
16. [Combination of a 3d-generation cephalosporin (cefotaxime or ceftazidime) and a new quinolone (pefloxacine) in the treatment of febrile episodes in neutropenic diseases (37 cases)].
Guy H; Caillot D; Solary E; Bielefeld P; Portier H; Kazmierczak A
Presse Med; 1987 Dec; 16(43):2172-5. PubMed ID: 2963306
[TBL] [Abstract][Full Text] [Related]
17. Lipopolysaccharide-binding protein: a possible diagnostic marker for Gram-negative bacteremia in neutropenic cancer patients.
Oude Nijhuis CSM; Vellenga E; Daenen SMGJ; van der Graaf WTA; Gietema JA; Groen HJM; Kamps WA; de Bont ESJM
Intensive Care Med; 2003 Dec; 29(12):2157-2161. PubMed ID: 14569424
[TBL] [Abstract][Full Text] [Related]
18. Safe fluoroquinolones prophylaxis in blood cancer patients with chemotherapy-induced neutropenia and Glucose-6-Phosphate-Dehydrogenase deficiency.
Sanna M; Caocci G; Orrù F; Ledda A; Vacca A; Piras E; Fozza C; Deias P; Tidore G; Dore F; La Nasa G
J Clin Pharm Ther; 2017 Dec; 42(6):733-737. PubMed ID: 28597476
[TBL] [Abstract][Full Text] [Related]
19. Factors associated with severe sepsis: prospective study of 94 neutropenic febrile episodes.
Jeddi R; Achour M; Amor RB; Aissaoui L; Bouterâa W; Kacem K; Lakhal RB; Abid HB; BelHadjAli Z; Turki A; Meddeb B
Hematology; 2010 Feb; 15(1):28-32. PubMed ID: 20132659
[TBL] [Abstract][Full Text] [Related]
20. Norfloxacin prophylaxis for neutropenic patients undergoing bone marrow transplantation.
Menichetti F; Felicini R; Bucaneve G; Aversa F; Greco M; Pasquarella C; Moretti MV; Del Favero A; Martelli MF
Bone Marrow Transplant; 1989 Sep; 4(5):489-92. PubMed ID: 2790326
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
